Form 4: Apellis VP Sells Shares for Tax Withholding

Apellis Pharmaceuticals' VP/Chief Accounting Officer, James Chopas, sold 726 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• James George Chopas, VP/Chief Accounting Officer of Apellis Pharmaceuticals, Inc. (APLS), reported a transaction.
• The transaction involved the disposition of 726 shares of Apellis Pharmaceuticals Common Stock.
• The shares were sold at a price of $19.7929 per share.
• The total value of shares sold was approximately $14,368.
• The sale was executed on January 20, 2026, and was made to cover tax withholding on Restricted Stock Units (RSUs) released on January 16, 2026.
• Following this transaction, James Chopas beneficially owns 51,869 shares of Common Stock directly.
• The transaction was made pursuant to a Rule 10b5-1 pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary sale of shares by an officer to cover tax obligations related to RSU vesting, which is a neutral event and does not indicate a change in management's confidence or company prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction for tax purposes and does not reflect broader industry trends or competitive positioning. Such sales are common for executives receiving equity compensation.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary sale for tax purposes and does not signal a change in company fundamentals or management's outlook.

Key Dates

Keywords

Apellis Pharmaceuticals, APLS, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, RSU, James Chopas, Officer Transaction